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expanded CD21- B cells in cGVHD patients also expressed
higher inhibitory receptors namely FCRL4, CD22 and CD85J,
chemokine receptors CD11c, CXCR3 and lower CD62L and
CCR7 compared with naïve (CD27-CD21+CD19+) and clas-
sical memory CD27+CD21+CD19+) B cells. Moreover, B cells
in patients with cGVHD had a lower proliferative potential
following B-cell receptor crosslinking compared with B cells
from patients with no GvHD or HC, a feature of exhaustion
associated with high expression of inhibitory receptors.
Finally, the frequencies of circulating CD21- B cells correlated
with cGvHD grade (r¼0.67; P ¼ .002) but not with time from
SCT (r¼0.28; P ¼ .15). These data suggest that CD21- B cells
may play a role in the pathogenesis of cGVHD and could be
used as as a marker of disease severity.55
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Chronic graft-versus-host disease (cGVHD) remains
a complication of allogeneic HCT and treatment remains
prednisone dependent with starting dose of 1mg/kg/day.
Rituximab shows efﬁcacy in steroid-refractory cGVHD sup-
porting B-cell pathogenesis. We hypothesized that anti-B cell
therapy delivered at cGVHD development is effective and
steroid-sparing. 35 patients (pts) with new-onset cGVHD,
requiring systemic steroid treatment at 1mg/kg/day, received
Rituximab 375-mg/m2 weekly x4 within ﬁrst month of
diagnosis. A second course was allowed if pts had less than
a partial response (PR) after 2 months.
Primary endpoints were six-month and 1y clinical
responses including steroid requirements. All 35 pts are
evaluable with 1.5y follow-up. Clinically meaningful
responses (deﬁned as pts with a PR or CR and prednisone
<0.25 mg/kg/day) were seen in 15/35 pts (43%, 13 CR; 2 PR)
at 6 months and remained 15/35 (43%, 11 CR, 4 PR) through
1y. There were 6 deaths from cGVHDwithin 1y of Rituximab.Table 1
Clinically meaningful responses (CR or PR and prednisone <0.25 mg/kg)
Responde
Median days to cGVHD 233 (136-
Pre-ritux CD19+ B cells/microliter 110 (rang
Pre-ritux naïve CD19+ CD38-, IgD+ CD27- B cells/
microliter
102 (0-11
Recovery of naïve B cells 1.5 y after Rituximab/microliter 63 (0-43
Pre-ritux IgG (mg/dl) 645 (224-
Pre-ritux BAFF (mg/dl) 2.8 (0.8-8
F/M pairs
n¼15
11 (73%)
9/15 FàM tested HY IgG positive preRitux All 11 res
became
seronegatOverall, cGVHD clinical response was predicted by naïve
CD19+CD38-IgD+CD27- B-cells pre-rituximab (p¼0.03), and
low BAFF (p¼0.007). B-cell-alloreactivity was assessed by HY
IgM, IgG, and HY speciﬁc B-cell quantiﬁcation. 15 cGVHD
patients were male with female donors (F/M) and 6 (38%)
tested HY IgM positive and 9 (56%) were HY IgG positive at
cGVHD diagnosis. Both HY IgM and IgG became undetectable
in all responders. In contrast, 3 of the 4 nonresponders
remained IgG HY positive and the other 1 redeveloped HY
IgG with cGVHD progression. Similarly, HY-antigen speciﬁc
B-cells were detected in 8/15 (53%) before rituximab and
recurred in 4/6 survivors with progression of cGVHD thus far.
This ﬁrst reported clinical trial of Rituximab and cortico-
steroids for new-onset cGVHD showed 46% clinically mean-
ingful responses through 1y with a steroid sparing effect. The
redevelopment of alloreactive B cells and HY IgG in associ-
ation with cGVHD progression suggests longer Rituximab
treatment-schedules or more potent B-cell inhibitors may
further improve cGVHD therapy.
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CD4+CD25+Foxp3+ regulatory T cells (Treg) play a central
role in the maintenance of immune tolerance. Impaired
recovery of Treg after HSCT is associated with the develop-
ment of cGVHD. In patients with cGVHD, Treg proliferate at
high levels but these cells are also highly susceptible to
apoptosis, leading to decreased survival and relative Treg
deﬁciency. To identify mechanisms that regulate Treg
susceptibility to apoptosis we used a new ﬂow cytometry-
based assay to measure mitochondrial membrane depolar-
ization in response to a panel of pro-apoptotic BH3 peptides
(BIM, BID, BAD, NOXA, PUMA, BMF, HRK). This allowed us to
compare BH3 peptide-induced mitochondrial membrane
depolarization (“priming”) in different T cell subsets; CD4
Treg, conventional CD4 T cells (CD4 Tcon), and CD8 T cells.
We also examined cytoplasmic expression of Bcl-2, Mcl1,
BclxL, Bim and cell surface expression of CD95 death receptor
(Fas). Functional susceptibility to apoptosis was measured
following in vitro stimulation with staurosporine or anti-rs n¼15 Nonresponders n ¼17 P-value
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